Akademik Veri Yönetim Sistemi
ESPE 2022, Rome, İtalya, 15 - 17 Eylül 2022, ss.343
Objective: We aimed to examine the auxological findings of
the girls diagnosed with idiopathic central precocious puberty
(CPP) at the end of the Gonadotropin-releasing hormone analogs
(GnRHa) treatment and to investigate the effect of related factors
on the height gain of those patients.
Methods: This study was designed as single-center, descriptive,
cross-sectional retrospective study. A total of 43 patients who were
diagnosed with idiopathic CPP and treated with GnRHa between
2012 - 2021 were included in to study.
Results: The mean chronological age (CA) of the subjects was
7.39 ± 0.76 years at the treatment initiation and 10.93 ± 0.21 at the
end of the therapy. The mean treatment duration was 3.96 ± 1.37
years. A decline in height standard deviation score (SDS) from 1.20
± 0.14 to 1.02 ± 0.06 during the therapy was observed (P<0.001).
The bone age (BA)/CA ratio was decreased and predictive adult
height (PAH) was increased at the end of the therapy (P<0.001;
P=0.001). Both the rates of overweightness and obesity were
increased (38.6% to 50% and 9% to 15.9%) when the treatment
onset compared with the end of therapy. At the end of the treatment; the mean body mass index (BMI) SDS of the overweight
patients was still higher compared to the normal-weight group and
the change in BMI SDS during the treatment in the overweight
group (BMI median: 1.39 to 1.81; ΔBMI: 0.42) was higher than the
change in the BMI SDS in the subjects with normal weight during
the treatment (BMI median: 0.32 to 0.46; ΔBMI: 0.14) (P<0.001).
There were no significant correlations between pre-treatment BMI
and height parameters (pre- and after-treatment height SDS as
well as pre- and after-treatment PAH SDS). While Δheight and
height velocity (HV) at the 1st year were higher at the patients
whose treatment was initiated before the age of 7 years; both preand after-treatment height and PAH SDS were similar in two
groups (P<0.0001; P<0.032; P=0.528; P=0.768; P=0.928; P=0.858).
Conclusion: A decrease in bone maturation rate and an increase
in PAH were observed with GnRHa treatment which had a positive
effect on height potential. The HV at 1st year and Δheight were higher when the treatment was initiated under the age of 7. An
increase in BMI during the therapy has been also demonstrated
especially in subjects who were overweight before treatment.